Phase I/II – Other

632 trials 274 recruiting

Filter these 632 trials by condition, country, sponsor and more.

Open in Search →

Identification and clinical relevance of an oxytocin-deficient state: randomized, crossover, placebo-controlled pilot physiopathological stu… Ended

2024-515588-67-00 Hypopituarism 2021-06-10
Guanabenz in VWM Ended

2023-503320-89-00 Vanishing White Matter 2021-05-31
Isatuximab in combination with pegenzileukin in RRMM previously exposed to anti-CD38 and anti- BCMA Ended

2024-514990-23-00 Cancer 2021-03-31
Dose Escalation of DF1001 in Patients With Advanced Solid Tumors, and Expansion in Selected Indications Ended

2023-503291-24-00 Locally Advanced or Metastatic Solid Tumors, and Expans 2021-03-17
Safety and efficacy of adding immunotherapy combined with stereotactic radiotherapy in patients with limited metastatic pancreatic cancer (M… Ended

2024-514598-23-00 Limited metastatic pancreatic cancer 2021-02-09
An Open-Label Phase I/II Study of Relatlimab (BMS-986016) with Nivolumab (BMS-936558) in Combination with 5-Azacytidine for Relapsed/Refract… Ended

2024-514948-89-00 Acute Myeloid Leukemia 2021-01-27
Phase 1b/2 study of liposomal annamycin (l-annamycin) in patients with previously treated metastatic soft-tissue sarcomas (ANNA-SARC) Ended

2024-517678-12-00 METASTATIC SOFT-TISSUE SARCOMAS AFTER FAILURE ON AT LE 2021-01-14
Study of Orally Administered CA-4948(IRAK4i) as a Monotherapy in patients with Acute Myelogenous Leukemia or Myelodysplastic Syndrome Ended

2024-513313-13-00 Acute Myelogenous Leukemia (AML) or higher-risk Myelody 2020-12-09
A study of Gilteritinib combined with chemotherapy to treat Children, Adolescents and Young Adults with Relapsed or Refractory Acute Myeloid… Ended

2024-512469-15-00 FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Dupli 2020-12-08
A phase I study evaluating safety and efficacy of Hepatic Intra- Arterial administration of ipilimumab in combination with Intra- venous niv… Ended

2023-506156-25-00 Advanced hepatocellular carcinoma 2020-11-13
A Phase 1b/2 Study of Abemaciclib Plus Chemotherapy and/or Chemoimmunotherapy in Pediatric and Young Adult Patients with Relapsed/Refractory… Ended

2023-506778-11-00 Relapsed/Refractory Solid Tumors 2020-11-11
Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants with Melanoma (KEYMAK… Ended

2023-506313-21-00 PD-1 refractory melanoma 2020-08-03
Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melano… Ended

2023-506314-51-00 Stage IIIB or IIIC or IIID melanoma 2020-07-31
Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refracto… Ended

2023-506312-41-00 PD-1 refractory melanoma 2020-07-30
“Phase I/II, Multicenter, Open-label, Clinical and Pharmacokinetic Study of Lurbinectedin (PM01183) in Combination with Pembrolizumab in Pat… Ended

2024-514206-31-00 Small cell lung cancer (SCLC). 2020-07-09
Phase-I/II trial for relapsed or refractory AML patients combining cytarabine and mitoxantrone with venetoclax (TUD-RELAX1-070) Ended

2024-514018-12-00 female and male adult patients with acute myeloid leuke 2020-04-06
Study of Pembrolizumab combined with Ataluren in Patients with metastatic pMMR and dMMR colorectal cancer adenocarcinomas or metastatic dMMR… Ended

2023-509457-31-00 metastatic colon cancer, advanced cancer of the colon 2019-09-01
Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunoch… Ended

2023-507498-16-00 Diffuse Large B-Cell Lymphoma (DLBCL) 2019-07-02
Efficacy and safety of tisotumab vedotin (HuMax®-TF-ADC) monotherapy and in combination in recurrent or Stage IVB cervical cancer Ended

2023-508832-68-00 Recurrent or stage IVB cervical cancer 2019-03-28
Metro-PD1: a phase I/II trial evaluating anti-PD1 (Nivolumab) in combination with metronomic chemotherapy in children and teenagers with ref… Ended

2024-513470-22-00 Progressive or refractory paediatric solid tumor 2019-03-22
MK-4280 and Pembrolizumab in Hematologic Malignancies Ended

2023-503587-17-00 Hematologic malignancies 2019-03-20
An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread Ended

2023-508207-21-00 Advanced Malignant Tumors 2019-02-08
Phase 1/2 Dose Finding, Safety and Efficacy Study of Ibrutinib in Pediatric Subjects with Chronic Graft Versus Host Disease (cGVHD) Ended

2023-507330-24-00 Chronic Graft Versus Host Disease (cGVHD) 2019-02-07
Study of subcutaneous nivolumab monotherapy with or without Recombinant Human Hyaluronidase PH20 (rHuPH20) Ended

2023-503554-12-00 lung cancer; kidney cancer; melanoma; liver cancer; col 2019-01-09